Navigation Links
Bioheart, Inc., Announces Management Change
Date:7/11/2008

SUNRISE, Fla., July 11 /PRNewswire-FirstCall/ -- Bioheart, Inc., (Nasdaq: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, announced today that Doug Owens, Director, Clinical Affairs, will assume responsibility for Bioheart's regulatory and clinical strategy for its investigational MyoCell(R) Therapy clinical trials from Richard T. Spencer, IV, who served as Bioheart's Vice President, Clinical Affairs and Physician Relations. Spencer has decided to leave Bioheart to pursue other opportunities, but has agreed to be available through the end of August to consult with Bioheart on the sale and distribution of the Bioheart 3370 Heart Failure Monitor as well as ongoing clinical trial activities.

"Rich developed an excellent infrastructure for our clinical trial program and regulatory process and we are sorry to see him leave," said Howard J. Leonhardt, Bioheart's CEO and Chief Technology Officer. "We believe we are well-positioned with Doug's experience in managing the MARVEL Trial to continue our enrollment momentum as we advance our clinical program in pursuit of regulatory approval and commercialization of this therapy to treat congestive heart failure patients."

"We are excited that Rich has agreed to work with us in a consulting capacity, as he has the background and skills that are key to a successful launch of our new product," said Leonhardt.

ABOUT BIOHEART

Bioheart, Inc. (Nasdaq: BHRT'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
4. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
5. Bioheart, Inc. to Transfer to Nasdaq Capital Market
6. Bioheart, Inc., Added to Russell Microcap Index
7. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
8. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
9. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
10. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
11. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument ... Buffers, Valves, Guages, Seals), Accessories, Services, End User ... 2019” provides a detailed overview of the major ... strategies impacting the preparative and process chromatography market ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... Siemens Medical Solutions, (http://www.usa.siemens.com/healthcareit ) continues ... clinical and financial workflows through,Soarian(R), its next-generation, ... Assembly and Annual Meeting of the,Radiological Society ... to 30 at,McCormick Place in Chicago (Booth ...
... Human Health Business, Creates a Global Leader in, Animal ... ... Projects, KENILWORTH, N.J., ... it has completed the,acquisition of Organon BioSciences N.V., creating a stronger ...
... /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS, Nasdaq: PXSL) today announced ... Plan which closed on 9 November 2007. Shareholders ... up to $5,000 worth of,shares each at the ... placement. A total of 2,496 shareholders participated ...
Cached Biology Technology:Siemens Customers Innovate Their Clinical and Financial Workflows with Help from Soarian 2Siemens Customers Innovate Their Clinical and Financial Workflows with Help from Soarian 3Schering-Plough Completes Acquisition of Organon BioSciences 2Schering-Plough Completes Acquisition of Organon BioSciences 3Schering-Plough Completes Acquisition of Organon BioSciences 4Schering-Plough Completes Acquisition of Organon BioSciences 5Pharmaxis Closes Share Purchase Plan 2
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming the ... at international borders. Over the past decade, ePassports, biometric ... to self process through border control via eGates and ... of airports, seaports, and land borders across the globe. ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... 2010 - Novocure reported today that patients with advanced ... in survival time when tumor treating fields (TTF) therapy ... outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, ... center in Switzerland, presented the data at the European ...
... have reported direct evidence that taking up smoking results in ... results were reported at the 35th Congress of the European ... link between smoking and cancer has been established for decades, ... Institute of Cancer Studies, Birmingham, who presented the results. Smoking ...
... at Chicago College of Medicine have found how gene expression ... unusual types of breast tumors. Their findings may offer new ... 8 issue of the Journal of Biological Chemistry, ... Approximately 70 percent of breast cancers express the estrogen receptor. ...
Cached Biology News:Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer 2Study reveals cancer-linked epigenetic effects of smoking 2Clue to unusual drug-resistant breast cancers found 2